Neurodevelopmental impairments in children with septo-optic dysplasia spectrum conditions: a systematic review.

Autism spectrum disorder Neurobehavioural impairments Neurodevelopmental impairments Optic nerve hypoplasia Septo-optic dysplasia

Journal

Molecular autism
ISSN: 2040-2392
Titre abrégé: Mol Autism
Pays: England
ID NLM: 101534222

Informations de publication

Date de publication:
25 07 2023
Historique:
received: 18 05 2023
accepted: 10 07 2023
medline: 27 7 2023
pubmed: 26 7 2023
entrez: 25 7 2023
Statut: epublish

Résumé

Septo-optic dysplasia (SOD) is a rare condition diagnosed in children with two or more of the following: hypopituitarism, midline brain abnormalities, and optic nerve hypoplasia. Children with SOD experience varied visual impairment and endocrine dysfunction. Autistic-like behaviours have been reported; however, their nature and prevalence remain to be fully understood. The present systematic review aimed to explore the type and prevalence of neurodevelopmental impairments in children with SOD spectrum conditions. The search was conducted in PubMed, EMBASE, and PsycInfo. Hand-searching reference lists of included studies was conducted. All peer-reviewed, observational studies assessing behavioural and cognitive impairments or autism spectrum disorder (ASD) symptoms in children (< 18 years) with SOD, optic nerve hypoplasia, and SOD-plus were included. Studies were excluded if they did not report standardised measures of neurodevelopmental impairments or ASD outcomes. From 2132 screened articles, 20 articles reporting data from a total of 479 children were included in prevalence estimates. Of 14 studies assessing cognitive-developmental outcomes, 175 of 336 (52%) children presented with intellectual disability or developmental delay. A diagnosis of ASD or clinical level of symptoms was observed in 65 of 187 (35%) children across five studies. Only five studies assessed for dysfunction across behavioural, emotional, or social domains and reported impairments in 88 of 184 (48%) of children assessed. Importantly, high heterogeneity among the samples in relation to their neuroanatomical, endocrine, and optic nerve involvement meant that it was not possible to statistically assess the relative contribution of these confounding factors to the specific neurodevelopmental phenotype. This was further limited by the variation in study designs and behavioural assessments used across the included studies, which may have increased the risk of information bias. This systematic review suggests that the prevalence of neurodevelopmental impairments in children within the SOD spectrum may be high. Clinicians should therefore consider including formal assessments of ASD symptoms and neurodevelopmental impairments alongside routine care. There is, additionally, a need for further research to define and validate a standardised battery of tools that accurately identify neurodevelopmental impairments in SOD spectrum conditions, and for research to identify the likely causal mechanisms.

Sections du résumé

BACKGROUND
Septo-optic dysplasia (SOD) is a rare condition diagnosed in children with two or more of the following: hypopituitarism, midline brain abnormalities, and optic nerve hypoplasia. Children with SOD experience varied visual impairment and endocrine dysfunction. Autistic-like behaviours have been reported; however, their nature and prevalence remain to be fully understood. The present systematic review aimed to explore the type and prevalence of neurodevelopmental impairments in children with SOD spectrum conditions.
METHODS
The search was conducted in PubMed, EMBASE, and PsycInfo. Hand-searching reference lists of included studies was conducted. All peer-reviewed, observational studies assessing behavioural and cognitive impairments or autism spectrum disorder (ASD) symptoms in children (< 18 years) with SOD, optic nerve hypoplasia, and SOD-plus were included. Studies were excluded if they did not report standardised measures of neurodevelopmental impairments or ASD outcomes.
RESULTS
From 2132 screened articles, 20 articles reporting data from a total of 479 children were included in prevalence estimates. Of 14 studies assessing cognitive-developmental outcomes, 175 of 336 (52%) children presented with intellectual disability or developmental delay. A diagnosis of ASD or clinical level of symptoms was observed in 65 of 187 (35%) children across five studies. Only five studies assessed for dysfunction across behavioural, emotional, or social domains and reported impairments in 88 of 184 (48%) of children assessed.
LIMITATIONS
Importantly, high heterogeneity among the samples in relation to their neuroanatomical, endocrine, and optic nerve involvement meant that it was not possible to statistically assess the relative contribution of these confounding factors to the specific neurodevelopmental phenotype. This was further limited by the variation in study designs and behavioural assessments used across the included studies, which may have increased the risk of information bias.
CONCLUSIONS
This systematic review suggests that the prevalence of neurodevelopmental impairments in children within the SOD spectrum may be high. Clinicians should therefore consider including formal assessments of ASD symptoms and neurodevelopmental impairments alongside routine care. There is, additionally, a need for further research to define and validate a standardised battery of tools that accurately identify neurodevelopmental impairments in SOD spectrum conditions, and for research to identify the likely causal mechanisms.

Identifiants

pubmed: 37491272
doi: 10.1186/s13229-023-00559-0
pii: 10.1186/s13229-023-00559-0
pmc: PMC10369759
doi:

Types de publication

Systematic Review Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

26

Subventions

Organisme : Medical Research Council
ID : MR/V038060/1
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4389-94
pubmed: 20160081
J Child Neurol. 2017 Aug;32(9):797-803
pubmed: 28482731
Dev Med Child Neurol. 2012 Nov;54(11):1018-24
pubmed: 22924461
J Autism Dev Disord. 1999 Feb;29(1):45-56
pubmed: 10097994
EClinicalMedicine. 2020 Jan 09;19:100224
pubmed: 32140665
Eur J Pediatr. 2008 Nov;167(11):1269-76
pubmed: 18231810
Acta Paediatr. 2003;92(3):301-8
pubmed: 12725544
Eur J Hum Genet. 2010 Apr;18(4):393-7
pubmed: 19623216
Dev Med Child Neurol. 1984 Jun;26(3):395-400
pubmed: 6734957
AJNR Am J Neuroradiol. 2014 Aug;35(8):1586-92
pubmed: 24763416
Acta Paediatr. 2018 Mar;107(3):484-489
pubmed: 29172231
Dev Med Child Neurol. 1994 Mar;36(3):191-7
pubmed: 7511120
Curr Treat Options Neurol. 2013 Feb;15(1):78-89
pubmed: 23233151
Brain Sci. 2020 Aug 01;10(8):
pubmed: 32752249
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):20953-8
pubmed: 24297883
Br J Ophthalmol. 2010 Oct;94(10):1358-62
pubmed: 20576785
Res Dev Disabil. 2013 Dec;34(12):4310-8
pubmed: 24210356
Neurology. 2000 Apr 25;54(8):1701-3
pubmed: 10762523
Mol Psychiatry. 2015 May;20(5):640-6
pubmed: 25092245
Eur Child Adolesc Psychiatry. 1998 Sep;7(3):131-6
pubmed: 9826299
Dev Med Child Neurol. 1993 Jun;35(6):490-501
pubmed: 8504891
Pediatrics. 2008 Mar;121(3):e653-9
pubmed: 18250116
Neurosci Biobehav Rev. 2017 May;76(Pt A):87-98
pubmed: 28434591
J Autism Dev Disord. 2011 Nov;41(11):1593-4; author reply 1595-7
pubmed: 21336526
Dev Med Child Neurol. 2010 Oct;52(10):917-21
pubmed: 20370811
Neurosci Biobehav Rev. 2022 Sep;140:104770
pubmed: 35803395
Acta Ophthalmol. 2014 Sep;92(6):563-70
pubmed: 24119069
Eye Brain. 2019 Oct 18;11:37-47
pubmed: 31695544
Acta Paediatr. 2005 Oct;94(10):1421-6
pubmed: 16299874
J Autism Dev Disord. 1994 Oct;24(5):659-85
pubmed: 7814313
Dev Med Child Neurol. 2014 Jan;56(1):66-72
pubmed: 24000901
J Child Neurol. 2018 Oct;33(11):693-699
pubmed: 29944054
PLoS One. 2013;8(3):e59048
pubmed: 23554967
Dev Med Child Neurol. 1984 Jun;26(3):311-22
pubmed: 6734946
J Clin Endocrinol Metab. 2012 Apr;97(4):E694-9
pubmed: 22319038
Hum Psychopharmacol. 2011 Jun-Jul;26(4-5):271-81
pubmed: 21751251
J Clin Endocrinol Metab. 2010 Oct;95(10):E198-203
pubmed: 20660044

Auteurs

Amy Mann (A)

Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. amy.mann@kcl.ac.uk.

Arameh Aghababaie (A)

Homerton Healthcare NHS Trust, Homerton University Hospital, London, UK.

Jennifer Kalitsi (J)

Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, Child and Family Health Nursing, King's College London, London, UK.

Daniel Martins (D)

Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
NIHR Maudsley Biomedical Research Centre, South London and Maudsley NHS Trust, London, UK.

Yannis Paloyelis (Y)

Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Ritika R Kapoor (RR)

Department of Paediatric Endocrinology, Variety Children's Hospital, King's College Hospital NHS Foundation Trust, London, UK.
Faculty of Life Sciences and Medicine, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH